OncoTherapy Science Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	-813	-1,285	-1,116	-2,570
Depreciation & Amortization	-	-	-	16
Loss (Gain) From Sale of Assets	-	154	21	547
Other Operating Activities	-2	-2	-17	-3
Change in Accounts Receivable	-63	87	276	-247
Change in Inventory	-4	25	131	-189
Change in Accounts Payable	21	-158	-240	385
Change in Other Net Operating Assets	46	-48	151	-12
Operating Cash Flow	-815	-1,227	-794	-2,073
Capital Expenditures	-	-2	-4	-456
Other Investing Activities	-	-31	-16	-11
Investing Cash Flow	-	-33	-20	-467
Issuance of Common Stock	1,178	676	-	1,478
Repurchase of Common Stock	-1	-	-	-
Other Financing Activities	-56	-5	95	-
Financing Cash Flow	1,121	671	95	1,478
Net Cash Flow	306	-589	-719	-1,062
Free Cash Flow	-815	-1,229	-798	-2,529
Free Cash Flow Margin	-108.67%	-201.47%	-70.37%	-219.34%
Free Cash Flow Per Share	-3.12	-5.78	-4.14	-13.49
Cash Interest Paid	1	-	-	-
Cash Income Tax Paid	2	2	2	2
Levered Free Cash Flow	-512.75	-937	-231.88	-1,782
Unlevered Free Cash Flow	-512.13	-937	-231.88	-1,782
Change in Working Capital	-	-94	318	-63

Source: S&P Global Market Intelligence. Standard template. Financial Sources.